• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688677.SS
Share

Qingdao NovelBeam Technology Co.,Ltd. Stocks

CN¥ 66.67Last Updated 09.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.36B

CN¥ 66.67
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Qingdao NovelBeam Technology Co., Ltd. is a global provider of optical components and advanced solutions for the medical, life science, laser, and micro-display projection industries. Its comprehensive offerings include specialized medical endoscopy devices such as endoscopes, camera couplers, camera lenses, and light source modules. Additionally, the company supplies a range of optical products covering medical optics, industrial and laser applications, and biometric systems. Established in 2003, the firm maintains its headquarters in Qingdao, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 00:49

What do analysts think about Trump's announced Russia-Ukraine energy ceasefire?

11.10.2026 21:01

IPO roundup: Firmus collapse sends AI funding warning; DeepSeek seeking $12 bln

11.10.2026 09:19

Twelve killed in attack on Riyadh airport

10.10.2026 16:01

Small caps last week: Webull risks, Levi’s outlook, Vaxcyte trial success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026